Robot-Assisted Minimally Invasive Surgery for Brainstem Hemorrhage
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 142
- Locations
- 6
- Primary Endpoint
- Survival rate
Study Overview
Brief Summary
The purpose of this clinical trial is to observe the improvements in clinical symptoms and imaging outcomes for brainstem hemorrhage using robot-assisted stereotactic puncture, evaluate the clinical efficacy and safety of this treatment, and explore the development of a high-precision, intelligent, and individualized microsurgical diagnosis and treatment process for brainstem hemorrhage. The main questions it aims to address are:
- Establish a multi-center clinical database for brainstem hemorrhage.
- Clinically observe and evaluate the intervention effects of robot-assisted stereotactic puncture on brainstem hemorrhage, compare it with the traditional conservative treatment control group, and investigate its efficacy and impact on patient survival, motor evoked potentials, and the degree of neurological deficits.
- Optimize the Artificial Intelligence (AI) algorithm-based robotic surgical assistance system, and explore the prediction of preoperative brainstem hematoma stability and hematoma path planning.
Participants in the experimental group will:
- Undergo robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture
- Receive conservative non-surgical treatment.
If there is a control group: the researchers will compare the conservative non-surgical treatment group to evaluate the effectiveness of robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥18 years at randomization；
- •Diagnosed with brainstem hemorrhage via imaging (CT, CTA, etc.)；
- •Hematoma volume ≥3 mL；
- •Glasgow Coma Scale (GCS) score of 3-12；
- •Available for surgery within 48 hours after onset；
- •Modified Rankin Scale (mRS) score ≤ 1 prior to this hemorrhage；
- •Informed consent obtained in accordance with national laws, regulations, and applicable ethics committee requirements.
- •Patients will be excluded if they meet any of the following criteria:
- •Hematoma involving other regions such as the supratentorial compartment, basal ganglia, thalamus, midbrain, or ventricles.
- •Radiologically confirmed cerebral vascular abnormalities including ruptured aneurysms, arteriovenous malformations (AVMs), or Moyamoya disease; hemorrhagic transformation of ischemic infarcts; or recent (within 1 year) recurrence of intracerebral hemorrhage；
- •Any irreversible coagulation disorder or known coagulopathy; platelet count <100,000/µL; INR >1.4; or use of anticoagulant medication within 7 days before the current hemorrhage；
- •Current or probable pregnancy；
- •Patients with concurrent severe illness likely to influence outcome assessment；
- •Difficulty in follow-up or poor compliance due to any cause.
Exclusion Criteria
- Not provided
Arms & Interventions
Robot-assisted minimally invasive puncture and aspiration surgery
The intervention group will receive robot-assisted stereotactic puncture for brainstem hemorrhage
Intervention: Robot-assisted minimally invasive puncture and aspiration surgery (Procedure)
Robot-assisted minimally invasive puncture and aspiration surgery
The intervention group will receive robot-assisted stereotactic puncture for brainstem hemorrhage
Intervention: Standard medical management (Other)
Standard medical management
The control group will undergo conventional medical conservative management.
Intervention: Standard medical management (Other)
Outcomes
Primary Outcomes
Survival rate
Time Frame: 60 days
60 days survival rate after follow-up
Secondary Outcomes
- ICU length of stay(60 days)
- Brainstem hematoma clearance rate on postoperative days 1, 3, and 7(1, 3, and 7 days)
- Incidence of related complications within 14 days, including pneumonia, aphasia, seizures, and lower-extremity deep vein thrombosis(14 days)
- Costs during hospitalization(60 days)
- Ordinal shift in mRS scores at 60 days and 6 months(60 days and 6 months)
- Favorable functional outcome at 60 days and 6 months (mRS 0-1)(60 days and 6 months)
- Functional independence at 60 days and 6 months (mRS 0-2)(60 days and 6 months)
- Health-related quality of life (HRQoL) at 60 days and 6 months, assessed by the EQ-5D-5L questionnaire(60 days and 6 months)
- Utility-weighted mRS at 60 days and 6 months(60 days and 6 months)
- Cognitive function at 60 days and 6 months(60 days and 6 months)
- Total length of hospital stay(60 days)
Investigators
Yanbing Yu
Chief of Neurosurgery
China-Japan Friendship Hospital